|
〕 that would overcome the problematic dietary, drug interaction, and monitoring issues associated with warfarin therapy. In 2006, its manufacturer AstraZeneca announced that it would withdraw pending applications for marketing approval after reports of ] (liver damage) during trials, and discontinue its distribution in countries where the drug had been approved (Germany, Portugal, Sweden, Finland, Norway, Iceland, Austria, Denmark, France, Switzerland, Argentina and Brazil).〔cite press release |publisher=AstraZeneca |date=February 14, 2006 |url=http://www.astrazeneca.com/Media/Press-releases/Article/20060214--AstraZeneca-Decides-to-Withdraw-Exanta |title=AstraZeneca Decides to Withdraw Exanta |accessdate=2012-07-16 }}〕 ==Method of action== Ximelagatran, a direct thrombin inhibitor, was the first member of this class that can be taken orally. It acts solely by inhibiting the actions of ethyl and hydroxyl groups with hydrogen). 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Ximelagatran」の詳細全文を読む スポンサード リンク
|